Compare Stocks: CLLS, WVE, SDGR, and IMTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$2.76 +0.2%	$3.04	$2.48 ▼ $5.48	$276.44M	2.91	37,860 shs	2,720 shs
IMTX Immatics	$8.96 +3.4%	$9.75	$5.05 ▼ $12.41	$1.20B	1.32	455,714 shs	112,680 shs
SDGR Schrodinger	$15.25 +0.7%	$15.40	$10.94 ▼ $23.02	$1.13B	1.62	1.34 million shs	508,672 shs
WVE WAVE Life Sciences	$5.62 +1.9%	$5.98	$5.02 ▼ $21.73	$1.11B	-1.26	3.89 million shs	1.95 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	0.00%	-3.17%	-16.67%	-30.38%	-6.78%
IMTX Immatics	0.00%	-4.63%	-12.96%	-19.74%	+33.64%
SDGR Schrodinger	0.00%	+1.14%	-10.31%	+22.20%	-22.48%
WVE WAVE Life Sciences	0.00%	-5.16%	-11.98%	-24.73%	-36.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$2.76 +0.2%	$3.04	$2.48 ▼ $5.48	$276.44M	2.91	37,860 shs	2,720 shs
IMTX Immatics	$8.96 +3.4%	$9.75	$5.05 ▼ $12.41	$1.20B	1.32	455,714 shs	112,680 shs
SDGR Schrodinger	$15.25 +0.7%	$15.40	$10.94 ▼ $23.02	$1.13B	1.62	1.34 million shs	508,672 shs
WVE WAVE Life Sciences	$5.62 +1.9%	$5.98	$5.02 ▼ $21.73	$1.11B	-1.26	3.89 million shs	1.95 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	0.00%	-3.17%	-16.67%	-30.38%	-6.78%
IMTX Immatics	0.00%	-4.63%	-12.96%	-19.74%	+33.64%
SDGR Schrodinger	0.00%	+1.14%	-10.31%	+22.20%	-22.48%
WVE WAVE Life Sciences	0.00%	-5.16%	-11.98%	-24.73%	-36.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLLS Cellectis	2.83	Moderate Buy	$7.00	154.08% Upside
IMTX Immatics	2.63	Moderate Buy	$20.80	132.27% Upside
SDGR Schrodinger	2.33	Hold	$20.25	32.79% Upside
WVE WAVE Life Sciences	2.94	Moderate Buy	$22.76	305.43% Upside

Current Analyst Ratings Breakdown

Latest CLLS, WVE, SDGR, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	WVE WAVE Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$13.00
8/3/2026	WVE WAVE Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	WVE WAVE Life Sciences	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$31.00 ➝ $22.00
7/31/2026	WVE WAVE Life Sciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $19.00
7/31/2026	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$15.00 ➝ $12.00
7/29/2026	SDGR Schrodinger	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	WVE WAVE Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	CLLS Cellectis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	WVE WAVE Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	SDGR Schrodinger	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/23/2026	IMTX Immatics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLLS Cellectis	$79.59M	3.47	N/A	N/A	$0.76 per share	3.63
IMTX Immatics	$37.30M	32.19	N/A	N/A	$4.09 per share	2.19
SDGR Schrodinger	$254.91M	4.42	N/A	N/A	$4.94 per share	3.09
WVE WAVE Life Sciences	$42.73M	25.89	N/A	N/A	$3.10 per share	1.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLLS Cellectis	-$67.59M	-$0.67	N/A	N/A	N/A	-89.51%	-80.66%	-20.51%	8/6/2026 (Estimated)
IMTX Immatics	-$222.26M	-$1.99	N/A	N/A	N/A	-572.35%	-47.36%	-39.35%	8/12/2026 (Estimated)
SDGR Schrodinger	-$103.26M	-$1.41	N/A	N/A	N/A	-40.61%	-30.85%	-15.32%	8/5/2026 (Estimated)
WVE WAVE Life Sciences	-$204.38M	-$1.09	N/A	N/A	N/A	-309.73%	-50.36%	-40.06%	N/A

Latest CLLS, WVE, SDGR, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	IMTX Immatics	-$0.4844	N/A	N/A	N/A	$11.73 million	N/A
8/6/2026	H1 2026	CLLS Cellectis	-$0.2630	N/A	N/A	N/A	$11.05 million	N/A
8/5/2026	Q2 2026	SDGR Schrodinger	-$0.4145	N/A	N/A	N/A	$47.19 million	N/A
7/30/2026	Q2 2026	WVE WAVE Life Sciences	-$0.2998	-$0.34	-$0.0403	-$0.34	$7.45 million	$2.27 million
5/12/2026	Q1 2026	IMTX Immatics	-$0.42	-$0.50	-$0.08	-$0.50	$9.79 million	$8.81 million
5/11/2026	Q1 2026	CLLS Cellectis	-$0.2583	-$0.18	+$0.0783	-$0.18	$11.04 million	$7.55 million
5/5/2026	Q1 2026	SDGR Schrodinger	-$0.56	-$0.81	-$0.25	-$0.81	$47.57 million	$58.59 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLLS Cellectis	1.13	1.52	1.52
IMTX Immatics	N/A	8.78	8.78
SDGR Schrodinger	N/A	2.74	2.74
WVE WAVE Life Sciences	N/A	9.99	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLLS Cellectis	63.90%
IMTX Immatics	64.41%
SDGR Schrodinger	79.05%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
CLLS Cellectis	16.41%
IMTX Immatics	3.30%
SDGR Schrodinger	10.10%
WVE WAVE Life Sciences	24.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLLS Cellectis	290	100.34 million	83.87 million	Optionable
IMTX Immatics	260	134.07 million	N/A	Optionable
SDGR Schrodinger	790	73.83 million	66.37 million	Optionable
WVE WAVE Life Sciences	240	197.05 million	149.17 million	Optionable

CLLS, WVE, SDGR, and IMTX Headlines

Recent News About These Companies

Wedbush Cuts WAVE Life Sciences (NASDAQ:WVE) Price Target to $12.00

August 3 at 1:36 AM | americanbankingnews.com

Citigroup Cuts WAVE Life Sciences (NASDAQ:WVE) Price Target to $19.00

August 3 at 1:36 AM | americanbankingnews.com

Wells Fargo Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

August 1 at 12:13 AM | theglobeandmail.com

Wave Life Sciences (WVE) Receives a Buy from RBC Capital

August 1 at 12:13 AM | theglobeandmail.com

Wave outlines WVE-007 Phase IIa in BMI 35-50 obesity, while projecting cash runway into Q3 2028

August 1 at 2:12 PM | seekingalpha.com

Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript

August 1 at 2:12 PM | finance.yahoo.com

WAVE Life Sciences (NASDAQ:WVE) Downgraded to "Strong Sell" Rating by Wall Street Zen

August 1 at 1:45 AM | americanbankingnews.com

Wall Street Zen Downgrades WAVE Life Sciences (NASDAQ:WVE) to Strong Sell

August 1 at 1:11 AM | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Announces Quarterly Earnings Results

July 31 at 8:55 PM | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Given New $19.00 Price Target at Citigroup

July 31 at 4:53 PM | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Given New $12.00 Price Target at Wedbush

July 31 at 9:23 AM | marketbeat.com

WAVE Life Sciences Q2 Earnings Call Highlights

July 30, 2026 | marketbeat.com

Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates

July 30, 2026 | zacks.com

Wave Life Sciences: Q2 Earnings Snapshot

July 30, 2026 | stamfordadvocate.comS

Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

July 30, 2026 | globenewswire.com

WAVE Life Sciences Ltd. $WVE Shares Sold by Elmind Capital LP

July 28, 2026 | marketbeat.com

Affinity Asset Advisors LLC Decreases Stake in WAVE Life Sciences Ltd. $WVE

July 25, 2026 | marketbeat.com

Wave Life Sciences (WVE) Stock Looks Cheap On Price But Expensive On Sales

July 24, 2026 | finance.yahoo.com

Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026

July 23, 2026 | globenewswire.com

Zacks Research Upgrades WAVE Life Sciences (NASDAQ:WVE) to "Strong-Buy"

July 23, 2026 | marketbeat.com

WAVE Life Sciences (WVE) to Release Quarterly Earnings on Thursday

July 23, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, WVE, SDGR, and IMTX Company Descriptions

Cellectis NASDAQ:CLLS

$2.76 +0.01 (+0.18%)

As of 02:19 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Immatics NASDAQ:IMTX

$8.96 +0.30 (+3.41%)

As of 02:27 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Schrodinger NASDAQ:SDGR

$15.25 +0.11 (+0.73%)

As of 02:27 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

WAVE Life Sciences NASDAQ:WVE

$5.62 +0.11 (+1.91%)

As of 02:27 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLLS, WVE, SDGR, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLLS, WVE, SDGR, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLLS, WVE, SDGR, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, WVE, SDGR, and IMTX Company Descriptions

Cellectis NASDAQ:CLLS

Immatics NASDAQ:IMTX

Schrodinger NASDAQ:SDGR

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLLS, WVE, SDGR, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLLS, WVE, SDGR, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLLS, WVE, SDGR, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, WVE, SDGR, and IMTX Company Descriptions

Cellectis NASDAQ:CLLS

Immatics NASDAQ:IMTX

Schrodinger NASDAQ:SDGR

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools